Open access Original research

Trauma Surgery & Acute Care Open

Safety or speed? Assessing alternative vascular access for angiography after resuscitative endovascular balloon occlusion of the aorta (REBOA) in severe pelvic trauma patients

Yau-Ren Chang , ¹ Yu-Tung Wu , ² Szu An Chen , ³ Chih-Yuan Fu , ⁴ Chi-Tung Cheng , ⁵ Ling-Wei Kuo , ⁶ Jen Fu Huang , ⁴ Chien-Hung Liao , ^{4,7} Chi-Hsun Hsieh , ^{4,8}

¹Trauma and Emergency Surgery, Far Eastern Memorial Hospital, New Taipei City, Taiwan

²Trauma and Emergency Surgery, Chang Gung Memorial Hospital Linkou Main Branch, Taoyuan, Taiwan

³Trauma and Acute Care Surgery, Chang Gung Memorial Hospital Linkou, Taoyuan, Taiwan

⁴Trauma and Emergency Surgery, Chang Gung Memorial Hospital Linkou, Taoyuan, Taiwan

⁵Trauma and Emergency Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan ⁶Chang Gung Memorial Hospital Linkou, Taoyuan, Taiwan ⁷Medicine, Chang Gung University, Taoyuan, Taiwan ⁸Chang Gung University, Taoyuan, Taiwan

Correspondence to

Dr Chi-Hsun Hsieh; hsieh0818@cgmh.org.tw

Received 11 June 2024 Accepted 27 November 2024

© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.

To cite: Chang Y-R, Wu Y-T, Chen SA, *et al. Trauma Surg Acute Care Open* 2025;**10**:e001530.

ABSTRACT

Introduction Pelvic fractures often result in life-threatening bleeding and hemodynamic instability. Resuscitative endovascular balloon occlusion of the aorta (REBOA) has emerged as a promising strategy for patients with severe pelvic fractures, facilitating subsequent hemostatic interventions. Transcatheter arterial embolization (TAE) is a well-established procedure for managing pelvic fractures accompanied by hemorrhage.

Ideally, an angiographic access point distinct from the initial REBOA placement is sought to maintain REBOA deflation without complete removal, thereby preventing hemodynamic instability during the procedure. However, in cases of extreme and severe pelvic trauma, gaining access for REBOA is already challenging, not to mention the additional difficulty posed by subsequent angiographic access.

This study aims to assess the challenges associated with gaining access in cases where successful TAE was ultimately performed, particularly in the context of severe pelvic trauma. We investigate the complexities surrounding access management and its implications for patient outcomes.

Methods We conducted a retrospective analysis of patients who presented with pelvic fractures and underwent sequential REBOA and TAE procedures at our institution between 2017 and 2023. We excluded patients with Abbreviated Injury Scores (AIS) ≥3 in systems other than the pelvis, those who underwent TAE prior to REBOA, and cases of suboptimal REBOA insertion.

We collected demographic data, injury characteristics, details of the REBOA and TAE procedures, information on complications, and data on patient survival. The primary endpoints of our analysis included overall survival and the success of TAE (defined as post TAE mean arterial pressure (MAP) ≥65 mm Hg). Secondary endpoints encompassed the duration details of two interventions.

Results Between 2017 and 2023, a total of 17 patients were included in this study. Among this cohort, 12 (70.6%) were male, with a median age of 51 years.

Overall survival was 23.5%. Patients were grouped into angiography after REBOA deflation (AAD) or angiography after REBOA removal (AAR). AAR group was younger (39.0 vs 63.0, p=0.030) and had higher Shock Index at triage (2.30 vs 1.10, p=0.015). More patient

WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ Resuscitative endovascular balloon occlusion of the aorta (REBOA) is used to control hemorrhage in severe cases, and transcatheter arterial embolization (TAE) is an established procedure for managing hemorrhagic pelvic fractures.
- ⇒ However, securing vascular access for TAE after REBOA remains challenging.

WHAT THIS STUDY ADDS

⇒ This study highlights that angiography after REBOA removal (AAR) is associated with a higher rate of post-TAE mean arterial pressure ≥65 mm Hg and a shorter duration from angiography room arrival to successful cannulation compared with angiography after REBOA deflation.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ The findings of this study indicate that AAR could be a preferable approach in severe pelvic fracture cases, potentially influencing clinical practice by providing a more efficient and effective method for vascular access in these critical situations.

whose post TAE MAP >=65 mm Hg was found in the AAR group, although no significant difference on overall survival (25.0% vs 22.2%, p=1.000). Angiographic cannulation times, pre-angiographic MAP, and amount of pre-angiographic transfusion of packed red blood cell were similar across groups.

Conclusion Our findings provide empirical insights into vascular access selection and suggest that AAR in the management of severe pelvic fractures can be beneficial, particularly when pre-angiographic resuscitation is sufficient. Larger studies are required to validate these observations and assess long-term outcomes.

Level of evidence III.

INTRODUCTION

Pelvic trauma poses a significant challenge in trauma care, constituting 3% of skeletal injuries. ¹⁻³ Patients afflicted with pelvic fractures are typically



young and present with elevated overall Injury Severity Scores (ISS) ranging from 25 to 48.⁴ Despite advancements in trauma care, mortality rates remain elevated, especially among those experiencing hemodynamic instability. The primary contributors to this heightened mortality include rapid exsanguination, the inherent difficulty in achieving hemostasis, and the presence of associated injuries.^{2,3,5}

In response to this formidable challenge, resuscitative endovascular balloon occlusion of the aorta (REBOA) has emerged as a promising and innovative strategy for patients suffering from severe pelvic fractures.^{6 7} By temporarily occluding the aorta, REBOA provides a crucial window for subsequent hemostatic interventions, effectively managing hemorrhage in these high-stakes situations.⁸ Concurrently, transcatheter arterial embolization (TAE) stands as a well-established and effective procedure for addressing pelvic fractures associated with significant hemorrhage.^{6 9 10}

The synergy between REBOA and TAE presents a comprehensive approach to managing severe pelvic trauma. However, navigating the intricacies of vascular access becomes particularly challenging in cases of extreme and severe pelvic trauma. 11 12 The difficulty is compounded when considering the need for an angiographic access point distinct from the initial REBOA placement. This strategic requirement arises from the desire to maintain REBOA deflation without complete removal, a delicate balance crucial for preventing hemodynamic instability during subsequent angiographic procedures.

Although the integration of REBOA and TAE holds immense potential, the challenges regarding the route of vascular access and how TAE is ultimately performed remain a focal point of concern. The intricacies of securing access for REBOA, particularly in cases of severe pelvic trauma, significantly contribute to the complexity of treatment strategies. This study seeks to thoroughly examine the challenges of vascular access, specifically when TAE is required after REBOA in severe pelvic trauma cases. By diving deep into the complexities of access management, our goal is to clarify how these challenges affect patient outcomes and provide insights to refine clinical approaches in this critical area. This investigation aims to bridge a crucial knowledge gap, shedding light on the complexities of this integrated therapeutic approach and its impact on the overall care framework for patients with severe pelvic trauma.

PATIENTS AND METHODS Study design and population

We conducted a single-center, retrospective cohort study of patients with pelvic fractures and subsequently underwent sequential REBOA and TAE at our institution from January 2017 to December 2023. Patients were included if they received both REBOA and TAE as part of their management. Those with significant concurrent injuries, defined as an Abbreviated Injury Score (AIS) of 3 or greater in any body system other than the pelvis, were excluded. Patients who underwent TAE prior to REBOA and those with suboptimal REBOA insertion, as determined by post-procedural imaging or surgical notes, were also excluded.

Retrospective data were collected through a comprehensive review of electronic medical records, radiologic images, and procedural reports. The collected data encompassed demographic information, type and severity of pelvic injuries, details of REBOA procedure, details of TAE procedure and findings, complications, amounts of transfusions and patient outcome.

The study's primary outcome measures are overall survival and TAE successful rate. A successful TAE was defined as optimal embolization and achieving a mean arterial pressure (MAP) ≥65 mmHg after TAE. Secondary outcomes include the duration for which the REBOA device is inflated and taking effect, as well as the time span from patient's arrival at the emergency department (ED) to the successful cannulation in the angiography suite.

Study grouping

Patients were divided into two groups based on the timing of angiographic cannulation relative to the REBOA procedure: angiography after REBOA deflation (AAD) and angiography after REBOA removal (AAR). In the AAD group, angiographic cannulation occurs after REBOA is partially or fully deflated but not removed, necessitating an additional arterial access, typically established contralaterally, for subsequent TAE. Conversely, in the AAR group, patients undergo angiography after the REBOA is removed. Thus, angiographic cannulation can be directly inserted into the sheath used for the preceding REBOA, expediting the procedure.

Statistical analysis

Descriptive statistics were used to summarize demographic and clinical characteristics. Continuous variables were expressed as medians and IQRs, as appropriate. Categorical variables were summarized as counts and percentages. Non-parametric comparisons were conducted using the Mann-Whitney U test, whereas univariate analysis for identifying risk factors associated with mortality employed logistic regression. A p value <0.05 was considered statistically significant. All statistical analyses were performed using IBM SPSS V.25 for Windows.

Ethical considerations

This study was conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments. This study was approved by the Institutional Review Board (IRB) of Chang Gung Memorial Hospital, Taoyuan city, Taiwan on August 1, 2022 (approval number: 201902275B0). Due to the retrospective nature of the study, the requirement for informed consent was waived.

RESULTS

During the 6-year period from 2017 to 2023, after excluding 10 patients who was not fit for our study, we enrolled 17 patients with pelvic fractures who underwent both REBOA and TAE procedures (see figure 1). Among 10 excluded patients, 2 of them was due to failed REBOA attempts, resulting from the kinking of the catheters during REBOA placement. The majority of enrolled patients were male (12 patients, 70.6%), with a median age of 51 years (IQR 37 years). Motor vehicle collisions were the leading cause of injury, accounting for 76.5% of cases (13 patients). Prior to REBOA, 29.4% of patients experienced cardiac arrest. Overall, the survival rate was 23.5%, with only 4 patients surviving to hospital discharge. Notably, 17.6% of patients arrived at the emergency department in a traumatic out-of-hospital cardiac arrest (OHCA) status. Among the factors analyzed for mortality risk, only the body temperature at ED arrival was found to be significant (OR=0.308, p=0.039) (see table 1).

The AAR group had a significantly lower median age (39.0 years vs 63.0 years, p=0.030) and a significantly higher Shock




Figure 1 Study population and protocol of the current study. AIS, Abbreviated Injury Scores; MAP, mean arterial pressure; OS, overall survival; REBOA, resuscitative endovascular balloon occlusion of the aorta; TAE, transcatheter arterial embolization.

Index at triage (2.30 vs 1.10, p=0.015) compared with the AAD group (see table 2). However, no statistical disparities were found between the groups regarding trauma mechanism, ratio of traumatic OHCA (12.5% vs 22.2%, p=1.000), temperature (35.40°C vs 34.00°C, p=0.193), Glasgow Coma Scale (GCS) (3.8 vs 9.5, p=0.663), MAP at ED arrival (32.20 mm Hg vs 80.15 mm Hg, p=0.630), Injury Severity Score (ISS) (13.0 vs 15.0, p=0.697), ratio of associated abdominal injury (25.0% vs 55.6%, p=0.335), pre-angiography MAP (61.00 mm Hg vs 79.30 mm Hg, p=0.149), arterial contrast leakage (62.5% vs 77.8%, p=0.620), laboratory parameters, or PRBC transfusion before TAE (10.0 IU vs 12.0 IU, p=0.883).

Although more patients in the AAR group achieved a post-TAE MAP \geq 65 mm Hg compared with the AAD group (75.0% vs 22.2%, p=0.044), there were no significant differences in OS (25.0% vs 22.2%, p=1.000) or survival 72 hours after TAE (37.5% vs 44.4%, p=0.968). Additionally, the AAR group exhibited a significantly shorter duration from angio-room arrival to successful cannulation (5.5 min vs 16.0 min, p=0.038) compared with the AAD group. However, TAE duration, REBOA placement procedure duration, and PRBC transfusion volume 24 hours after TAE were comparable across both groups.

As shown in table 3, there was one case in the AAD group where preperitoneal pelvic packing was performed after REBOA placement, and the patient underwent TAE after preperitoneal packing. Due to severe inguinal crushing injury, arterial access on the contralateral side for angiography is not feasible. Furthermore, the inability to remove the REBOA arises from its severe compression by preperitoneal packing. Consequently, a novel femoral arterial access point proximal to the previous REBOA sheath becomes imperative to facilitate successful completion of TAE. During angiography, confirmation of contralateral external iliac traumatic transection further underscores the complexity and critical nature of the vascular injury management in this context. Additionally, there was another case in the AAR group where the patient received preperitoneal packing prior to TAE and subsequently had a favorable outcome, being discharged without major complications. In contrast, none of our patients received vasopressors or underwent pelvic fixation before TAE.

The most common indication for choosing AAR over AAD was injury to the contralateral internal iliac artery, observed in 50% of AAR patients (four patients), either due to initial trauma or iatrogenic injury. The findings of angiography in our study were listed below: bilateral internal iliac artery and associated branches bleeding (n=4), unilateral internal iliac artery and associated artery bleeding (n=8), unilateral internal iliac artery pseudoaneurysm (n=1), and no evidence of active bleeding (n=4). All of the relevant procedures were non-selective embolization over bilateral internal iliac arteries. Among all AAD patients, two of them underwent reinflation of the balloon due to severe

hemodynamic compromise during TAE, whereas one of these two patients had transient left leg hypoperfusion but recovered without complications.

DISCUSSION

The role of REBOA in the management of pelvic fracture

The introduction of REBOA presents a pivotal shift in the paradigm of managing complex pelvic fractures.³ This study highlights REBOA's integral role in stabilizing patients with severe pelvic trauma by providing temporary hemorrhagic control, which is crucial for facilitating subsequent definitive hemostatic interventions. Our findings found that the median MAP of post-REBOA is increased by 17.0 from pre-REBOA, aligning with previous research indicating REBOA's efficacy in hemodynamic stability among patients with traumatic hemorrhage when employed judiciously.¹³

The synergistic application of REBOA with TAE offers a comprehensive approach that addresses both immediate hemorrhage control and definitive bleeding source management, as suggested by Harfouche *et al.*¹⁴ However, the challenges in achieving vascular access for TAE after REBOA deployment, particularly in the context of severe trauma, underscore the need for advanced planning and procedural proficiency.

Our study is among the first to comprehensively discuss the technical and clinical considerations regarding vascular access route selection in patients with severe pelvic injury. Theoretically, the indication for inclusion into AAR or AAD was the presence of an injury. Typically, the decision would be based on physiology. Patients who are extremely labile would be better served in the AAD, whereas those who are stable could be in the AAR group. Deflation of REBOA without removal of REBOA catheter has the potential benefit that the REBOA can be reinflated whenever the patient's hemodynamics become unstable during TAE. The TAE procedure can be even performed with the partially inflated balloon. Therefore, the hemodynamic stability can be maintained more easily compared with those patients who had their REBOA catheter been removed before TAE.

Interestingly, our results revealed that there was no statistical difference between the AAD and AAR groups regarding their pre-TAE MAP (79.3 mm Hg vs 61.0 mm Hg, p=0.149) and the amount of PRBC transfusion before TAE (12.0 vs 10.0, p=0.883). This suggests that as long as patients can be adequately resuscitated to maintain hemodynamic stability, both AAR and AAD could be viable options for surgeons.

Furthermore, the severity of MAP drops during TAE, represented by the ratio of (Intra-angiography lowest MAP – Preangiography MAP)/Pre-angiography MAP, showed no significant difference between the two groups. Interestingly, there was even

Table 1 Demographic data and univariate analysis of risk factors affecting OS of patients with traumatic pelvic injury underwent REBOA followed by TAE (n=17)

followed by TAE (n=17)				
Variables	Numbers/median	%/IQR	OR	P value
Male	12	70.6	1.333	0.825
Age (year)	51	37	1.008	0.760
Mechanism				
MVA	13	76.5	0.000	0.999
Falling	4	23.5	_	
Traumatic OHCA	3	17.6	0.000	0.999
Temperature at ED arrival (°C)	35.0	2.8	0.308	0.039*
HR at ED arrival (bpm)	113.0	57.0	1.002	0.878
Shock index at ED arrival	1.5	1.4	1.236	0.660
MAP at ED arrival (mm Hg)	46.7	50.0	0.996	0.806
Pre-REBOA MAP (mm Hg)	42.0	22.3	1.016	0.647
Post-REBOA MAP (mm Hg)	59.0	25.9	0.986	0.731
Pre-angiography MAP (mm Hg)	69.0	29.4	1.012	0.714
Intra-angiography lowest MAP (mm Hg)	68.0	46.0	1.030	0.336
(Intra-angiography lowest MAP – Pre-angiography MAP)/Pre-angiography MAP (%)	22.0	36.5	4.938	0.490
Post-TAE MAP (mm Hg)	64.3	49.9	1.026	0.194
Post-TAE MAP ≥65 mm Hg	8	47.1	0.208	0.223
GCS at ED arrival	3.0	7.0	0.028	0.999
ISS	45.0	13.0	0.948	0.355
Open pelvic fracture	3	17.6	1.833	0.662
Associated abdominal injury	7	41.2	6.750	0.142
Y-B classification of pelvic fracture			-	
APC I	1	5.9		
APC II	3	17.6		
PC III	7	41.2		
LC II	2	11.8		
LC III	4	23.5		
PT-INR	1.70	0.70	0.714	0.798
Hb (g/dL)	9.60	2.75	0.130	0.623
SBE (mmol/L)	-13.55	-7.45	0.976	0.783
Lactate (mg/dL)	87.55	70.28	0.967	0.153
Procedure time of REBOA placement (min)	9.0	5.5	0.466	0.153
PRBC transfusion before TAE (U)	12.0	16.0	0.925	0.324
PRBC transfusion 24 hours after TAE (U)	18.0	16.0	1.045	0.268
Cardiac arrest before REBOA	5	29.4	0.000	0.999
Zone of REBOA placement			-	
Zone 1	4	23.5		
Zone 3	13	76.5		
REBOA access by cutdown	2	11.8	0.000	0.999
Duration of REBOA inflation (min)	107.0	83.5	0.516	0.994
Duration from ED arrival to cannulation (min)	147.0	80.5	0.979	0.170
Duration from angio-room arrival to cannulation (min)	7.0	12.0	0.966	0.569
Duration of angiographic cannulation (min)	67.0	34.5	1.001	0.952
Type of angiographic cannulation				
AAD	9	52.9	1.120	0.857
AAR	8	47.1	_	
				Continue

Table 1 Continued				
Variables	Numbers/median	%/IQR	OR	P value
Contrast medium during angiography (mL)	60.0	45.0	0.993	0.770
PPP	2	11.8	4.000	0.373
latrogenic vascular injury	1	5.9	-	
LOS (day)	10	39.0	-	
Survival 72 hours after TAE	7	41.2	-	
OS	4	23.5	-	

*P value < 0.05.

AAD, angiography after REBOA deflation; AAR, angiography after REBOA removal; APC, anterior-posterior compression; CE, contrast extravasation; CT, computed tomography; ED, emergent department; ED, emergency department; GCS, Glasgow Coma Scale; Hb, hemoglobin; HR, heart rate; IQR, interquartile range; ISS, Injury Severity Score; LC, lateral compression; LOS, length of stay; MAP, mean arterial pressure; MVA, motor vehicle accident; OHCA, out-of-hospital cardiac arrest; OR, odds ratio; OS, overall survival; PPP, pre-peritoneal pelvic packing; PRBC, packed red blood cell; PT-INR, international normalized ratio derived from prothrombin time; REBOA, resuscitative endovascular balloon occlusion of the aorta; SBE, standard base excess; TAE, transcatheter arterial embolization; Y-B classification, Young-Burgess classification

a trend toward a higher ratio in the AAD group then the AAR group (24.0% vs 2.0%, p=0.092).

These findings suggest that as long as adequate resuscitation can be achieved before TAE, the potential advantages of REBOA deflation might be mitigated, thereby making alternative arterial access methods feasible in clinical practice.

On the other hand, removal of REBOA before starting TAE was believed to be a way to accelerate vascular access and facilitate definitive hemostasis. In our study, we found that the duration from angio-room arrival to starting cannulation was significantly shorter in the AAR group than in the AAD group, whereas the time required for successful cannulation was similar between the two groups. Such results might be attributed to the combined effect of several factors including experiences of individual radiologists.

In addition to the AAR and AAD techniques, there are alternative approaches for performing TAE after REBOA under extreme conditions, such as partial REBOA or intermittent REBOA.¹⁵ Although these methods were not used or detailed in our study, we think they represent viable options at the discretion of the radiologist, depending on the clinical scenario and patient-specific factors.

A recent prospective randomized controlled trial¹⁷ involving 1388 patients undergoing coronary angiography and percutaneous coronary intervention demonstrated that ultrasound-guided puncture significantly enhanced the efficiency and overall success rate of arterial access. Similar to the above-mentioned study, we routinely employ ultrasound-guided puncture for every patient requiring arterial access for angiography. This approach helps mitigate operator bias and ensures consistency of successful arterial puncture in a short period of time across all cases.

One retrospective study reported by Awwad *et al*¹⁸ revealed that for the management of severe pelvic injuries, selective embolization had a superior overall survival rate compared with non-selective embolization. Additionally, the use of gelfoam as the sole embolizer had a greater survival benefit compared with those using a combination of gelfoam and coils. However, such differences were not observed in our cohort possibly due to the limited number of cases in the current study.



Table 2 Comparisons of characteristics between angiography after REBOA deflation (AAD) and angiography after REBOA removal (AAR) in patients with traumatic pelvic injury underwent REBOA followed by TAE (n=17)

Male (n/%) 6 (66.7) 7 (87.5) 0.294 Age (median year/IQR) 63.0 (20.5) 39.0 (27.8) 0.030* Mechanism (n/%) 1.000 MVA 7 (77.8) 6 (75.0) Falling 2 (22.2) 2 (25.0) Traumatic OHCA (n/%) 2 (22.2) 1 (12.5) 1.000 Temperature at ED arrival (median °C/IQR) 34.00 (2.45) 35.40 (3.55) 0.193 HR at ED arrival (mediani °C/IQR) 84.0 (28.5) 134.0 (19.0) 0.009* Shock index at ED arrival (median/IQR) 1.10 (0.80) 2.30 (2.55) 0.015* MAP at ED arrival (median/IQR) 52.00 (80.15) 37.00 (32.20) 0.630 Pre-REBOA MAP (mmHg/IQR) 42.70 (47.70) 40.65 (22.50) 0.499 URN MP (mHg/IQR) 79.30 (34.00) 61.00 (30.93) 0.149 Intra-angiography MAP (mHg/IQR) 79.30 (34.00) 61.00 (30.93) 0.149 Intra-angiography MAP (mHg/IQR) 24.0 (38.0) 2.0 (56.7) 0.092 Intra-angiography MAP (mHg/IQR) 2.0 (36.5) 89.15 (66.73) 0.36	lue
Mechanism (n/%) 1.000 MVA 7 (77.8) 6 (75.0) Falling 2 (22.2) 2 (25.0) Traumatic OHCA (n/%) 2 (22.2) 1 (12.5) 1.000 Temperature at ED arrival (median C/IQR) 34.00 (2.45) 35.40 (3.55) 0.193 HR at ED arrival (median bpm/IQR) 84.0 (28.5) 134.0 (19.0) 0.009* MAP at ED arrival (median/IQR) 52.00 (80.15) 37.00 (32.20) 0.630 MAP at ED arrival (mm Hg/IQR) 42.70 (47.70) 40.65 (22.50) 0.49e Pre-REBOA MAP (mm Hg/IQR) 42.70 (47.70) 57.85 (26.15) 0.847 Pre-REBOA MAP (mm Hg/IQR) 79.30 (34.00) 61.00 (30.93) 0.149 Intra-angiography MAP (mm Hg/IQR) 79.30 (34.00) 61.00 (30.93) 0.149 Intra-angiography Iowest MAP (mm Hg/IQR) 52.7 (35.65) 56.65 (37.28) 0.700 MAP (mm Hg/IQR) 62.30 (22.00) 89.15 (66.73) 0.136 (Pre-angiography MaP (%I)(R) 62.20 (22.20) 6 (75.0) 0.044* eS65 mm Hg (n/%) 62.23 (22.2) 6 (75.0) 0.63	4
MVA 7 (77.8) 6 (75.0) Falling 2 (22.2) 2 (25.0) Traumatic OHCA (n/%) 2 (22.2) 1 (12.5) 1.000 Temperature at ED arrival (median °C/IQR) 34.00 (2.45) 35.40 (3.55) 0.193 HR at ED arrival (median bpm/IQR) 84.0 (28.5) 134.0 (19.0) 0.009* Shock index at ED arrival (median/IQR) 1.10 (0.80) 2.30 (2.55) 0.015* MAP at ED arrival (median/IQR) 52.00 (80.15) 37.00 (32.20) 0.630 MAP at ED arrival (median/IQR) 52.00 (80.15) 37.00 (32.20) 0.630 Pre-REBOA MAP (mmHg/IQR) 66.70 (27.50) 57.85 (26.15) 0.499 URSTABEBOA MAP (mmHg/IQR) 66.70 (27.50) 57.85 (26.15) 0.847 Intra-angiography Iowest (mmHg/IQR) 52.7 (35.65) 56.65 (37.28) 0.700 MAP (mm Hg/IQR) 24.0 (38.0) 2.0 (56.7) 0.092 Post-TAE MAP (mmHg/IQR) 62.30 (22.0) 89.15 (66.73) 0.136 OPST-TAE MAP (mm Hg/IQR) 45.0 (15.0) 3.0 (3.8) 0.663 GCS at ED arrival (median/IQR) 45.0 (15.0) <td>0*</td>	0*
Falling 2 (2(2.2) 2 (25.0) Traumatic OHCA (n/%) 2 (22.2) 1 (12.5) 1.000 Temperature at ED arrival (median °C/IQR) 33.00 (2.45) 35.40 (3.55) 0.193 (median °C/IQR) 84.0 (28.5) 134.0 (19.0) 0.009* bpm/IQR) 1.10 (0.80) 2.30 (2.55) 0.015* (median/IQR) 1.10 (0.80) 2.30 (2.55) 0.015* (median/IQR) 1.10 (0.80) 37.00 (32.20) 0.630 (mm Hg/IQR) 1.10 (0.80) 37.00 (32.20) 0.630 (mm Hg/IQR) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.80) 1.10 (0.	0
Traumatic OHCA (n/%) 2 (22.2) 1 (12.5) 1.000 Temperature at ED arrival (median °C/IQR) 35.40 (3.55) 0.193 HR at ED arrival (median pmm/IQR) 84.0 (28.5) 134.0 (19.0) 0.009* Shock index at ED arrival (median/IQR) 1.10 (0.80) 2.30 (2.55) 0.015* MAP at ED arrival (mmHg/IQR) 52.00 (80.15) 37.00 (32.20) 0.630 MAP at ED arrival (mmHg/IQR) 42.70 (47.70) 40.65 (22.50) 0.499 Pre-REBOA MAP (mmHg/IQR) 66.70 (27.50) 57.85 (26.15) 0.847 Pre-REBOA MAP (mmHg/IQR) 79.30 (34.00) 61.00 (30.93) 0.149 Intra-angiography MAP (mmHg/IQR) 79.30 (34.00) 61.00 (30.93) 0.149 Intra-angiography lowest MAP (mmHg/IQR) 52.7 (35.65) 56.65 (37.28) 0.700 MAP (mmHg/IQR) 62.30 (22.00) 89.15 (66.73) 0.136 Post-TAE MAP (mm Hg/IQR) 62.30 (22.00) 89.15 (66.73) 0.136 GCS at ED arrival (median/IQR) 45.0 (15.0) 43.0 (13.0) 0.697 Open pelvic fracture (n/%) 45.0 (15.0) 43.0 (13.0) 0.697	
Temperature at ED arrival (median °C/IQR)	
(median °C/IQR) 84.0 (28.5) 134.0 (19.0) 0.009* bpm/IQR) 84.0 (28.5) 134.0 (19.0) 0.009* bpm/IQR) 1.10 (0.80) 2.30 (2.55) 0.015* MAP at ED arrival (median/IQR) 52.00 (80.15) 37.00 (32.20) 0.630 MAP at ED arrival (mmHg/IQR) 42.70 (47.70) 40.65 (22.50) 0.499 Pre-REBOA MAP (mmHg/IQR) 66.70 (27.50) 57.85 (26.15) 0.847 Pre-angiography MAP (mmHg/IQR) 79.30 (34.00) 61.00 (30.93) 0.149 Intra-angiography lowest MAP (mm Hg/IQR) 52.7 (35.65) 56.65 (37.28) 0.700 MAP (mm Hg/IQR) 24.0 (38.0) 2.0 (56.7) 0.092 Intra-angiography Iowest MAP/Pre-angiography MAP – (%/IQR) 66.75.0 0.66.7 0.044* 65 mm Hg (n/R) 62.20 (22.00) 89.15 (66.73) 0.136 Post-TAE MAP (mm Hg/IQR) 45.0 (15.0) 43.0 (13.0) 0.697 Open pelvic fracture (n/R) 45.0 (15.0) 43.0 (13.0) 0.697 Open pelvic fracture (n/%) 1 (11.1) 2 (25.0) 0.335 APC II	0
bpm/IQR Shock index at ED arrival (median/IQR) 1.10 (0.80) 2.30 (2.55) 0.015* (median/IQR) 52.00 (80.15) 37.00 (32.20) 0.630 (mmHg/IQR) 52.00 (80.15) 37.00 (32.20) 0.630 (mmHg/IQR) 79.30 (34.70) 40.65 (22.50) 0.499 IQR) 79.80 (34.00) 61.00 (30.93) 0.149 (mmHg/IQR) 79.30 (34.00) 89.15 (66.73) 0.700 (mmHg/IQR) 79.30 (34.00) 89.15 (66.73) 0.92 (mmTa-angiography MAP (mmHg/IQR) 89.15 (66.73) 0.136 (78.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79.00 (79.00) 79	3
(median/IQR) 52.00 (80.15) 37.00 (32.20) 0.630 MAP at ED arrival (mmHg/IQR) 52.00 (80.15) 37.00 (32.20) 0.630 Pre-REBOA MAP (mm Hg/IQR) 42.70 (47.70) 40.65 (22.50) 0.499 Post-REBOA MAP (mm Hg/IQR) 66.70 (27.50) 57.85 (26.15) 0.847 Pre-angiography MAP (mm Hg/IQR) 79.30 (34.00) 61.00 (30.93) 0.149 Intra-angiography MAP (mm Hg/IQR) 52.7 (35.65) 56.65 (37.28) 0.700 (Pre-angiography MAP (mm Hg/IQR) 24.0 (38.0) 2.0 (56.7) 0.092 (Pre-angiography MAP (mm Hg/IQR) 24.0 (38.0) 2.0 (56.7) 0.092 (Pre-angiography MAP (mm Hg/IQR) 62.30 (22.00) 89.15 (66.73) 0.136 (Pre-angiography MAP (mm Hg/IQR) 62.30 (22.00) 89.15 (66.73) 0.136 (Pre-angiography MAP (mm Hg/IQR) 62.30 (22.00) 89.15 (66.73) 0.136 (Pre-angiography MAP (mm Hg/IQR) 3.0 (38.0) 2.0 (56.7) 0.092 Post-TAE MAP (mm Hg/IQR) 42 (22.2) 6 (75.0) 0.04* Bost-TAE (median/IQR) 3.0 (9.5) 3.0 (3.8) <t< td=""><td>9*</td></t<>	9*
(mmHg/IQR) 42.70 (47.70) 40.65 (22.50) 0.499 Pre-REBOA MAP (mmHg/IQR) 66.70 (27.50) 57.85 (26.15) 0.847 Pre-angiography MAP (mmHg/IQR) 79.30 (34.00) 61.00 (30.93) 0.149 Intra-angiography MAP (mmHg/IQR) 52.7 (35.65) 56.65 (37.28) 0.700 MAP (mmHg/IQR) 24.0 (38.0) 2.0 (56.7) 0.092 Intra-angiography lowest MAP)/Pre-angiography MAP (%/IQR) 24.0 (38.0) 2.0 (56.7) 0.092 Post-TAE MAP (mmHg/IQR) 62.30 (22.00) 89.15 (66.73) 0.136 Post-TAE MAP (mmHg/IQR) 2 (22.2) 6 (75.0) 0.044* ≤65 mmHg (n/%) 3.0 (9.5) 3.0 (3.8) 0.663 ISS (median/IQR) 45.0 (15.0) 43.0 (13.0) 0.697 Open pelvic fracture (n/%) 45.0 (15.0) 43.0 (13.0) 0.697 Y-B classification of pelvic fracture (n/%) 5 (55.6) 2 (25.0) 0.335 APC I 1 (11.1) 0 (0.0)	5*
IQR Post-REBOA MAP (mm Hg/IQR) Fre-angiography MAP (mm Hg/IQR) Fre-angiography MAP (mm Hg/IQR) Fre-angiography lowest MAP (mm Hg/IQR) Fre-angiography lowest MAP (mm Hg/IQR) Fre-angiography lowest MAP (mm Hg/IQR) Fre-angiography MAP − Intra-angiography lowest MAP (mm Hg/IQR) Fre-angiography MAP − Intra-angiography lowest MAP)/Pre-angiography MAP − Intra-angiography MAP (%/IQR) Fre-angiography MaP (%/IQ	0
(mm Hg/IQR) (mm Hg/IQR) 61.00 (30.93) 0.149 Pre-angiography MAP (mm Hg/IQR) 79.30 (34.00) 61.00 (30.93) 0.149 Intra-angiography lowest MAP (mm Hg/IQR) 52.7 (35.65) 56.65 (37.28) 0.700 (Pre-angiography MAP – Intra-angiography MAP (%/IQR) 24.0 (38.0) 2.0 (56.7) 0.092 Post-TAE MAP (mm Hg/IQR) 62.30 (22.00) 89.15 (66.73) 0.136 Post-TAE MAP ≥ ≥65m Hg (n/%) 2 (22.2) 6 (75.0) 0.044* GCS at ED arrival (median/IQR) 3.0 (9.5) 3.0 (3.8) 0.663 ISS (median/IQR) 45.0 (15.0) 43.0 (13.0) 0.697 Open pelvic fracture (n/%) 1 (11.1) 2 (25.0) 0.576 Associated abdominal injury (n/%) 5 (55.6) 2 (25.0) 0.335 Y-B classification of pelvic fracture (n/%) APC I 1 (11.1) 2 (25.0) 0.335 APC II 1 (11.1) 2 (25.0)	9
(mm Hg/JQR) 1ntra-angiography lowest MAP (mm Hg/IQR) 52.7 (35.65) 56.65 (37.28) 0.700 (Pre-angiography MAP (mm Hg/IQR) 24.0 (38.0) 2.0 (56.7) 0.092 Intra-angiography MAP (%/IQR) 62.30 (22.00) 89.15 (66.73) 0.136 Post-TAE MAP (mm Hg/IQR) 62.30 (22.00) 89.15 (66.73) 0.136 Post-TAE MAP (mm Hg/IQR) 2 (22.2) 6 (75.0) 0.044* ≥65 mm Hg (n/%) 3.0 (9.5) 3.0 (3.8) 0.663 GCS at ED arrival (median/IQR) 45.0 (15.0) 43.0 (13.0) 0.697 Open pelvic fracture (n/%) 1 (11.1) 2 (25.0) 0.576 Associated abdominal injury (n/%) 5 (55.6) 2 (25.0) 0.335 Y-B classification of pelvic fracture (n/%) 1 (11.1) 0 (0.0)	7
MAP (mm Hg/lQR) (Pre-angiography MAP – Intra-angiography MAP) 24.0 (38.0) 2.0 (56.7) 0.092 Intra-angiography MAP (%/IQR) 62.30 (22.00) 89.15 (66.73) 0.136 Post-TAE MAP (mm Hg/ IQR) 62.30 (22.00) 89.15 (66.73) 0.136 Post-TAE MAP (mm Hg/ IQR) 2 (22.2) 6 (75.0) 0.044* ≥65 mm Hg (n/%) 3.0 (9.5) 3.0 (3.8) 0.663 GCS at ED arrival (median/IQR) 45.0 (15.0) 43.0 (13.0) 0.697 Open pelvic fracture (n/%) 1 (11.1) 2 (25.0) 0.576 Associated abdominal injury (n/%) 5 (55.6) 2 (25.0) 0.335 Y-B classification of pelvic fracture (n/%) - - APC II 1 (11.1) 0 (0.0) - APC III 1 (11.1) 2 (25.0) - APC III 1 (11.1) 1 (12.5) - LC II 1 (11.1) 1 (12.5) - LC III 1 (11.1) 1 (12.5) - PT-INR (median/IQR) 1.70 (0.85) 1.70 (0.70) 0.710 Hb (median g/dL/IQR) 960 (3.25) 9.50 (3.18) <t< td=""><td>9</td></t<>	9
Intra-angiography lowest MAP)/Pre-angiography MAP (%/IQR) Post-TAE MAP (mm Hg/IQR) 62.30 (22.00) 89.15 (66.73) 0.136 Post-TAE MAP 2 (22.2) 6 (75.0) 0.044* ≥65 mm Hg (n/%) 3.0 (9.5) 3.0 (3.8) 0.663 GCS at ED arrival (median/IQR) 45.0 (15.0) 43.0 (13.0) 0.697 Open pelvic fracture (n/%) 1 (11.1) 2 (25.0) 0.576 Associated abdominal injury (n/%) 5 (55.6) 2 (25.0) 0.335 Y-B classification of pelvic fracture (n/%) - - APC I 1 (11.1) 0 (0.0) - APC II 1 (11.1) 2 (25.0) - APC III 1 (11.1) 1 (12.5) - LC II 1 (11.1) 1 (12.5) - PT-INR (median/IQR) 1.70 (0.85) 1.70 (0.70) 0.710 Hb (median g/dL/IQR) 9.60 (3.25) 9.50 (3.18) 0.700 SBE (median mmol/L/IQR) -12.40 (6.25) -13.90 (18.75) 0.560 Lactate (median mg/dL/IQR) 93.25 (61.68) 78.55 (72.72) 0.834 HD (median U/IQR) 12.0 (9.0) <	0
IQR) Post-TAE MAP ≥65 mm Hg (n/%) 2 (22.2) 6 (75.0) 0.044* ≥65 mm Hg (n/%) 3.0 (9.5) 3.0 (3.8) 0.663 GCS at ED arrival (median/IQR) 45.0 (15.0) 43.0 (13.0) 0.697 Open pelvic fracture (n/%) 1 (11.1) 2 (25.0) 0.576 Open pelvic fracture (n/%) 5 (55.6) 2 (25.0) 0.335 Associated abdominal injury (n/%) 5 (55.6) 2 (25.0) 0.335 Y-B classification of pelvic fracture (n/%) 1 (11.1) 0 (0.0) - APC I 1 (11.1) 0 (0.0) - APC III 1 (11.1) 1 (12.5) - LC II 1 (11.1) 1 (12.5) - LC III 1 (11.1) 1 (12.5) - PT-INR (median/IQR) 1.70 (0.85) 1.70 (0.70) 0.710 Hb (median g/dL/IQR) 9.60 (3.25) 9.50 (3.18) 0.700 SBE (median mmol/L/IQR) -12.40 (6.25) -13.90 (18.75) 0.560 Lactate (median mg/ dL/IQR) 93.25 (61.68) 78.55 (72.72) 0.834 Procedure time of REBOA placement (median minute/IQR) 1	2
≥65 mm Hg (n/%) GCS at ED arrival (median/IQR) ISS (median/IQR) 45.0 (15.0) A3.0 (3.8) 0.663 Open pelvic fracture (n/%) Associated abdominal injury (n/%) Y-B classification of pelvic fracture (n/%) APC II APC III 1 (11.1) 1 (11.1) 2 (25.0) APC III 3 (33.3) 4 (50.0) LC II 1 (11.1) 1 (11.1) 1 (12.5) LC III 3 (33.3) 1 (12.5) PT-INR (median/IQR) 1.70 (0.85) 1.70 (0.70) O.710 Hb (median g/dL/IQR) PREC transfusion before TAE (median U/IQR) PRBC transfusion 24 18.0 (13.0) 3.0 (3.8) 3.0 (3.8) 3.0 (3.8) 43.0 (13.0) 0.697 0.697 0.697 0.697 0.697 0.697 0.796 0.335 1 (12.5) 1.70 (0.70) 0.710 1.70 (0.85) 1.70 (0.70) 0.710 1.70 (0.83) 0.734 1.70 (0.83) 0.734	6
(median/IQR) 45.0 (15.0) 43.0 (13.0) 0.697 Open pelvic fracture (n/%) 1 (11.1) 2 (25.0) 0.576 Associated abdominal injury (n/%) 5 (55.6) 2 (25.0) 0.335 Y-B classification of pelvic fracture (n/%) — — APC II 1 (11.1) 0 (0.0) — APC III 1 (11.1) 2 (25.0) — APC III 3 (33.3) 4 (50.0) — LC II 1 (11.1) 1 (12.5) — LC III 3 (33.3) 1 (12.5) — PT-INR (median/IQR) 1.70 (0.85) 1.70 (0.70) 0.710 Hb (median g/dL/IQR) 9.60 (3.25) 9.50 (3.18) 0.700 SBE (median mmol/L/IQR) —12.40 (6.25) —13.90 (18.75) 0.560 Lactate (median mg/dL/IQR) 93.25 (61.68) 78.55 (72.72) 0.834 dL/IQR) Procedure time of REBOA placement (median minute/IQR) 9.0 (3.5) 10.0 (8.3) 0.734 PRBC transfusion before TAE (median U/IQR) 12.0 (9.0) 10.0 (25.5) 0.883 P	4*
Open pelvic fracture (n/%) 1 (11.1) 2 (25.0) 0.576 Associated abdominal injury (n/%) 5 (55.6) 2 (25.0) 0.335 Y-B classification of pelvic fracture (n/%) — — APC I 1 (11.1) 0 (0.0) — APC III 1 (11.1) 2 (25.0) — APC III 3 (33.3) 4 (50.0) — LC II 1 (11.1) 1 (12.5) — LC III 3 (33.3) 1 (12.5) — PT-INR (median/IQR) 1.70 (0.85) 1.70 (0.70) 0.710 Hb (median g/dL/IQR) 9.60 (3.25) 9.50 (3.18) 0.700 SBE (median mmol/L/IQR) -12.40 (6.25) -13.90 (18.75) 0.560 Lactate (median mg/dL/IQR) 93.25 (61.68) 78.55 (72.72) 0.834 dL/IQR) Procedure time of REBOA placement (median minute/IQR) 9.0 (3.5) 10.0 (8.3) 0.734 PRBC transfusion before TAE (median U/IQR) 12.0 (9.0) 10.0 (25.5) 0.883 PRBC transfusion 24 18.0 (13.0) 14.0 (28.5) 0.529	3
(n/%) (n/%) 2 (25.0) 0.335 Associated abdominal injury (n/%) 5 (55.6) 2 (25.0) 0.335 Y-B classification of pelvic fracture (n/%) — — APC I 1 (11.1) 0 (0.0) — APC III 1 (11.1) 2 (25.0) — APC III 1 (11.1) 1 (12.5) — LC II 1 (11.1) 1 (12.5) — LC III 3 (33.3) 1 (12.5) — PT-INR (median/IQR) 1.70 (0.85) 1.70 (0.70) 0.710 Hb (median g/dL/IQR) 9.60 (3.25) 9.50 (3.18) 0.700 SBE (median mmol/L/IQR) -12.40 (6.25) -13.90 (18.75) 0.560 Lactate (median mg/dL/IQR) 93.25 (61.68) 78.55 (72.72) 0.834 dL/IQR) Procedure time of REBOA placement (median minute/IQR) 9.0 (3.5) 10.0 (8.3) 0.734 PRBC transfusion before TAE (median U/IQR) 12.0 (9.0) 10.0 (25.5) 0.883 PRBC transfusion 24 18.0 (13.0) 14.0 (28.5) 0.529	7
injury (n/%) Y-B classification of pelvic fracture (n/%) - APC I 1 (11.1) 0 (0.0) APC III 1 (11.1) 2 (25.0) APC III 3 (33.3) 4 (50.0) LC II 1 (11.1) 1 (12.5) LC III 3 (33.3) 1 (12.5) PT-INR (median/IQR) 1.70 (0.85) 1.70 (0.70) 0.710 Hb (median g/dL/IQR) 9.60 (3.25) 9.50 (3.18) 0.700 SBE (median mmol/L/IQR) -12.40 (6.25) -13.90 (18.75) 0.560 Lactate (median mg/dL/IQR) 93.25 (61.68) 78.55 (72.72) 0.834 dL/IQR) Procedure time of REBOA placement (median minute/IQR) 9.0 (3.5) 10.0 (8.3) 0.734 PRBC transfusion before TAE (median U/IQR) 12.0 (9.0) 10.0 (25.5) 0.883 PRBC transfusion 24 18.0 (13.0) 14.0 (28.5) 0.529	6
pelvic fracture (n/%) APC I 1 (11.1) 0 (0.0) APC II 1 (11.1) 2 (25.0) APC III 3 (33.3) 4 (50.0) LC II 1 (11.1) 1 (12.5) LC III 3 (33.3) 1 (12.5) PT-INR (median/IQR) 1.70 (0.85) 1.70 (0.70) 0.710 Hb (median g/dL/IQR) 9.60 (3.25) 9.50 (3.18) 0.700 SBE (median mmol/L/IQR) -12.40 (6.25) -13.90 (18.75) 0.560 Lactate (median mg/dL/IQR) 93.25 (61.68) 78.55 (72.72) 0.834 dL/IQR) Procedure time of REBOA placement (median minute/IQR) 9.0 (3.5) 10.0 (8.3) 0.734 PRBC transfusion before TAE (median U/IQR) 12.0 (9.0) 10.0 (25.5) 0.883 PRBC transfusion 24 18.0 (13.0) 14.0 (28.5) 0.529	5
APC II 1 (11.1) 2 (25.0) APC III 3 (33.3) 4 (50.0) LC II 1 (11.1) 1 (12.5) LC III 3 (33.3) 1 (12.5) PT-INR (median/IQR) 1.70 (0.85) 1.70 (0.70) 0.710 Hb (median g/dL/IQR) 9.60 (3.25) 9.50 (3.18) 0.700 SBE (median mmol/L/IQR) -12.40 (6.25) -13.90 (18.75) 0.560 Lactate (median mg/dL/IQR) 93.25 (61.68) 78.55 (72.72) 0.834 dL/IQR) Procedure time of REBOA placement (median minute/IQR) PRBC transfusion before TAE (median U/IQR) PRBC transfusion 24 18.0 (13.0) 14.0 (28.5) 0.529	
APC III 3 (33.3) 4 (50.0) LC II 1 (11.1) 1 (12.5) LC III 3 (33.3) 1 (12.5) PT-INR (median/IQR) 1.70 (0.85) 1.70 (0.70) 0.710 Hb (median g/dL/IQR) 9.60 (3.25) 9.50 (3.18) 0.700 SBE (median mmol/L/IQR) -12.40 (6.25) -13.90 (18.75) 0.560 Lactate (median mg/dL/IQR) 93.25 (61.68) 78.55 (72.72) 0.834 dL/IQR) Procedure time of REBOA placement (median minute/IQR) PRBC transfusion before TAE (median U/IQR) PRBC transfusion 24 18.0 (13.0) 14.0 (28.5) 0.529	
LC II 1 (11.1) 1 (12.5) LC III 3 (33.3) 1 (12.5) PT-INR (median/IQR) 1.70 (0.85) 1.70 (0.70) 0.710 Hb (median g/dL/IQR) 9.60 (3.25) 9.50 (3.18) 0.700 SBE (median mmol/L/IQR) -12.40 (6.25) -13.90 (18.75) 0.560 Lactate (median mg/dL/IQR) 93.25 (61.68) 78.55 (72.72) 0.834 dL/IQR) 9.0 (3.5) 10.0 (8.3) 0.734 Procedure time of REBOA placement (median minute/IQR) 10.0 (25.5) 0.883 PRBC transfusion before TAE (median U/IQR) 12.0 (9.0) 10.0 (25.5) 0.883 PRBC transfusion 24 18.0 (13.0) 14.0 (28.5) 0.529	
LC III 3 (33.3) 1 (12.5) PT-INR (median/IQR) 1.70 (0.85) 1.70 (0.70) 0.710 Hb (median g/dL/IQR) 9.60 (3.25) 9.50 (3.18) 0.700 SBE (median mmol/L/IQR) -12.40 (6.25) -13.90 (18.75) 0.560 Lactate (median mg/dL/IQR) 93.25 (61.68) 78.55 (72.72) 0.834 dL/IQR) 90. (3.5) 10.0 (8.3) 0.734 Procedure time of REBOA placement (median minute/IQR) 12.0 (9.0) 10.0 (25.5) 0.883 PRBC transfusion before TAE (median U/IQR) 18.0 (13.0) 14.0 (28.5) 0.529	
PT-INR (median/IQR) 1.70 (0.85) 1.70 (0.70) 0.710 Hb (median g/dL/IQR) 9.60 (3.25) 9.50 (3.18) 0.700 SBE (median mmol/L/IQR) -12.40 (6.25) -13.90 (18.75) 0.560 Lactate (median mg/dL/IQR) 93.25 (61.68) 78.55 (72.72) 0.834 Hocedure time of REBOA placement (median minute/IQR) 9.0 (3.5) 10.0 (8.3) 0.734 PRBC transfusion before TAE (median U/IQR) 12.0 (9.0) 10.0 (25.5) 0.883 PRBC transfusion 24 18.0 (13.0) 14.0 (28.5) 0.529	
Hb (median g/dL/IQR) 9.60 (3.25) 9.50 (3.18) 0.700 SBE (median mmol/L/IQR) -12.40 (6.25) -13.90 (18.75) 0.560 Lactate (median mg/dL/IQR) 93.25 (61.68) 78.55 (72.72) 0.834 dL/IQR) Procedure time of REBOA placement (median minute/IQR) 10.0 (8.3) 0.734 PRBC transfusion before TAE (median U/IQR) 12.0 (9.0) 10.0 (25.5) 0.883 PRBC transfusion 24 18.0 (13.0) 14.0 (28.5) 0.529	
SBE (median mmol/L/IQR) -12.40 (6.25) -13.90 (18.75) 0.560 Lactate (median mg/ dL/IQR) 93.25 (61.68) 78.55 (72.72) 0.834 Procedure time of REBOA placement (median minute/IQR) 9.0 (3.5) 10.0 (8.3) 0.734 PRBC transfusion before TAE (median U/IQR) 12.0 (9.0) 10.0 (25.5) 0.883 PRBC transfusion 24 18.0 (13.0) 14.0 (28.5) 0.529	0
Lactate (median mg/ dL/IQR) 93.25 (61.68) 78.55 (72.72) 0.834 Procedure time of REBOA placement (median minute/IQR) 9.0 (3.5) 10.0 (8.3) 0.734 PRBC transfusion before TAE (median U/IQR) 12.0 (9.0) 10.0 (25.5) 0.883 PRBC transfusion 24 18.0 (13.0) 14.0 (28.5) 0.529	0
dL/IQR) Procedure time of REBOA placement (median minute/IQR) 9.0 (3.5) placement (median minute/IQR) 10.0 (8.3) placement (median minute/IQR) 0.734 placement (median minute/IQR) PRBC transfusion before TAE (median U/IQR) 12.0 (9.0) placement (median minute/IQR) 10.0 (25.5) placement (median minute/IQR) 0.883 placement (median minute/IQR) PRBC transfusion 24 18.0 (13.0) placement (median minute/IQR) 14.0 (28.5) placement (median minute/IQR)	0
Placement (median minute/IQR) PRBC transfusion before 12.0 (9.0) 10.0 (25.5) 0.883 TAE (median U/IQR) PRBC transfusion 24 18.0 (13.0) 14.0 (28.5) 0.529	4
TAE (median U/IQR) PRBC transfusion 24 18.0 (13.0) 14.0 (28.5) 0.529	4
	3
U/IQR)	9
Cardiac arrest before 4 (44.4) 1 (12.5) 0.294 REBOA (n/%)	4

Table 2 Continued			
Variables	AAD (n=9)	AAR (n=8)	P value
Zone of REBOA placement (n/%)			0.082
Zone 1	4 (44.4)	0 (0.0)	
Zone 3	5 (55.6)	8 (100.0)	
REBOA access by cutdown (n/%)	0 (0.0)	2 (25.0)	0.206
Duration of REBOA inflation (median minute/ IQR)			
Total	112.0 (85.5)	77.0 (127.3)	0.178
Zone 1	130.5 (119.5)	_	-
Zone 3	75.0 (62.5)	77.0 (127.3)	1.000
Duration from ED arrival to cannulation (median minute/IQR)	135.0 (87.0)	153.5 (87.3)	0.563
Duration from angio- room arrival to cannulation (median minute/IQR)	16.0 (18.5)	5.5 (10.8)	0.038*
Duration of angiographic cannulation (median minute/IQR)	67.0 (65.5)	66.5 (18.8)	0.810
latrogenic vascular injury (n/%)	0 (0.0)	1 (12.5)	0.471
LOS (median day/IQR)	9.0 (29.8)	22.0 (50.5)	0.226
Survival 72 hours after TAE (n/%)	4 (44.4)	3 (37.5)	0.968
Hemostatic intervention (n/%) before TAE			
PPP	1 (11.1)	1 (12.5)	-
Laparotomy	1 (11.1)	0 (0.0)	-
No	7 (77.8)	7 (87.5)	_
OS (n/%)	2 (22.2)	2 (25.0)	1.000

APC, anterior-posterior compression; CE, contrast extravasation; CT, computed tomography; ED, emergency department; GCS, Glasgow Coma Scale; Hb, hemoglobin; HR, heart rate; IQR, interquartile range; ISS, Injury Severity Score; LC, lateral compression; LOS, length of stay; MAP, mean arterial pressure; MVA, motor vehicle accident; OHCA, out-of-hospital cardiac arrest; OS, overall survival; PPP, pre-peritoneal pelvic packing; PRBC, packed red blood cell; PT-INR, international normalized ratio derived from prothrombin time; REBOA, resuscitative endovascular balloon occlusion of the aorta; SBE, standard base excess; TAE, transcatheter arterial embolization; Y-B classification, Young-Burgess classification.

Outcome and complications of REBOA utilization in severe pelvic fracture

Although REBOA is a promising technique, it is not without complications. Complications associated with the use of REBOA in the management of pelvic fractures include access site complications like hematoma and pseudoaneurysm, ¹² ¹⁹ which may result in lower limb ischemia and consequently lead to amputation of the limbs in severe cases. ²⁰ Technical difficulties in the insertion of the catheter and the potential for iatrogenic injury during the procedure are also reported. ¹¹ In our study, one patient experienced an iatrogenic injury to the external iliac artery, which necessitated TAE of the injured iliac artery after the removal of the REBOA catheter.

The risks associated with prolonged occlusion, such as reperfusion injury and limb ischemia, must be carefully weighed against the benefits, especially in cases where delays to definitive care are anticipated.²¹ The balance between maintaining aortic occlusion to ensure hemodynamic stability and mitigating the risks associated with ischemia is a delicate one that requires further

Demographics	aphics		Trauma	Trauma characteristics		REBOA	A details					Angiography details	details		Outcomes	ies	
No.	Age	S/I at arrival	SSI	Associated injury	MAP ≥65 mm Hg after REBOA	C/A ever	ver Zone	Access method	Inflation I duration	Access duration	Embolizer	Angio duration	Post TAE MAP ≥65mmHg	Post TAE survival in 72hours	FOS	SO	Remark
AAD																	
-	70s	0.7	29	Tibia fx, L-spine fx	>-	z	m	P/C	154	2	Gelatin	34	z	z	2	z	
2	50s	N/A	20	Pneumothorax, mesocolon injury	z	>-	-	P/C	149	28	Gelatin+Coils	113	z	z	0	z	PPP causing REBOA removal failure, contralateral iliac artery transaction
m	909	1.3	57	Spleen injury, mesentery injury	>-	z	-	P/C	112	19	Gelatin	29	z	>-	22	>	
4	70s	N/A	45	Hemothorax, lung contusion	>-	>-	-	P/C	112	7	Gelatin	37	z	z	0	z	CPCR at OR without ROSC
2	909	0.8	41	Pneumo-hemothorax	>-	>-	m	P/C	79	9	Gelatin+Coils	50	z	z	N/A	z	REBOA adjustment at ED
9	30s	1.5	41	Mesentery injury	z	>-	-	P/C	259	30	Gelatin+Coils	105	z	z	2	z	Manpower shortage leading to delayed angiography
7	909	0.7	48	Pneumo-hemothorax	>-	z	m	P/C	75	18	Gelatin	156	z	>-	32	z	Agitation requiring sedation during angiography
∞	80s	1.1	20	Liver laceration	z	z	m	P/C	51	9	Gelatin	66	>	>-	29	>	
6	20s	1.9	20	SDH, spleen injury, lung contusion	z	z	m	P/C	27	16	Gelatin	55	>	>-	20	z	Expired due to brain stem failure
AAR																	
10	30s	4.0	41	Lung contusion, SDH	z	z	m	P/C	137	15	Gelatin	63	>	z	N/A	z	Altered access due to iatrogenic external iliac artery injury
11	30s	3.9	25	Femoral fx, urethral injury	z	z	e	P/C	107	5	Gelatin	54	>	>-	12	>	PPP performed
12	10s	1.2	20	No	z	z	m	P/C	∞	m	Gelatin+Coils	9/	>	>-	4	z	Reinflation of REBOA after TAE due to shock
13	40s	4.2	38	Heart contusion, femoral fx	>-	>	m	Cut-down	15	-	Gelatin	73	>	z	N/A	z	
14	50s	2.1	36	Spleen injury	>-	z	m	P/C	138	14	Gelatin	52	z	Z	N/A	z	Avoiding any BT, as Jehovah's Witness
15	20s	6:0	45	Hemothorax, aortic injury	>-	z	m	P/C	147	-	Gelatin	55	>	z	-	z	Contralateral internal iliac artery traumatic occlusion
16	e0s	2.3	48	SAH, leg traumatic amputation	Z	z	m	Cut-down	6	9	Gelatin	70	z	z	N/A	z	Angiography paused due to shock, retrying after REBOA completed
17	20s	2.3	20	EDH, perineal laceration	z	z	m	P/C	47	7	Gelatin+Coils	73	>-	>-	55	>-	Contralateral internal iliac artery traumatic dissection
	-														:		

AAD, angiography after REBOA deflation: AAR, angiography after REBOA removal; BT, blood transtusion; CIA, cardiac arrest; CPCR, cardiopulmonary cerebral resuscitation; ED, emergency department; EDH, epidural hemorrhage; F, female; fx, fracture; ISS, Injury Severity Score; LOS, length of stay; M, male; MVA, motor vehicle acrident; N, not recorded; OR, operation room; OS, overall survival; PIC, percutaneous; PPP, pre-pertioneal packing; REBOA, resuscitative endovascular balloon occlusion of the aorta; ROSC, return of spontaneous circulation; SAH, subarachnoid hemorrhage; SDH, subdural hemorrhage; SII, Shock Index; TAE, transcatheter arterial embolism; Y, yes.



investigation. In our study, although the median aortic occlusion time (overall: 107.0 min; Zone 1: 130.5 min; Zone 3: 75.0 min) exceeded the optimal durations suggested in the studies by Norii *et al*, Matsumura *et al*, and Sadeghi *et al* (30–45 min for Zone 1 and 60–90 min for Zone 3),^{22–24} none of the patients developed limb ischemia or required subsequent amputation. This may be due to the timely provision of definitive treatment at our trauma center.

Limitations

The limitations of our study, including its single-center retrospective design and small sample size of 17 patients over 6 years, restrict the generalizability and statistical power of our findings. We acknowledge that the small sample size of 17 cases limits the reliability of using logistic regression analysis, as it increases the risk of overfitting and instability in the results. Consequently, we have chosen to address potential confounders qualitatively in our discussion. Moreover, the primary objective of this study was to share our experiences with the application of both AAR and AAD methods for patients requiring TAE after REBOA, rather than to establish the superiority of one method over the other. Given this focus, we determined that logistic regression analysis was not essential for this study. Furthermore, the study timeframe is 6 years and the resuscitation protocols as well as the equipment available may change overtime, which could have influenced outcomes. Variations in the REBOA and TAE procedures, such as the partial or intermittent REBOA method, arterial access sites, and embolic materials, contribute to data heterogeneity, complicating result interpretation. These factors collectively underscore the need for caution when extrapolating our conclusions to broader clinical practice.

CONCLUSION

In summary, this cohort study compared the outcomes of different vascular access methods in the combined REBOA-TAE approach for patients with severe pelvic fractures. Our findings suggest that both AAR and AAD are viable options for patients requiring TAE after REBOA. The choice between these techniques should be guided by the clinical scenario, patient-specific factors, and the discretion of the radiologist. Further research with larger cohorts is essential to validate these findings and explore long-term outcomes.

Acknowledgements The authors gratefully acknowledge that all team members dedicate their best efforts to care for patients with acute abdominal diseases.

Contributors Y-R C, MD: Contributed to the study design, data collection, and manuscript drafting. Y-T W, MD: Participated in data analysis, interpretation of the results, and manuscript revision. S-A C, MD: Assisted in patient recruitment and data collection. C-Y F, MD: Involved in the study design and critical revision of the manuscript. C-P H, MD: Contributed to data analysis and manuscript editing. CTC, MD: Assisted in data collection and literature review. L-W K, MD: Involved in the interpretation of results and manuscript drafting. J-F H, MD: Contributed to the statistical analysis and manuscript revision. C-H L, MD: Involved in the conception of the study and supervision of the project. C-H H, MD: Served as the principal investigator, overseeing the entire study process, including design, execution, data analysis, and manuscript preparation. C-H H, MD is the guarantor of the study, ensuring the accuracy and integrity of the research. In the preparation of this manuscript titled "Safety or Speed? Assessing Alternative Vascular Access for Angiography Following Resuscitative Endovascular Balloon of the Aorta (REBOA) in Severe Pelvic Trauma Patients," Al technology was utilized for assistance in writing and editing tasks. Al Technology Used: OpenAl's GPT-4 language model. Reason for Use: To enhance the clarity, coherence, and overall quality of the manuscript text, ensuring it meets academic standards and effectively communicates the study's findings. Tasks performed: The AI was used to: Edit and refine the manuscript text for clarity and readability. Generate the key messages and cover letter based on provided content. Summarize complex information succinctly. Ensure the language used is precise and appropriate for an academic publication. The AI was not involved in data analysis, interpretation of results, or any other substantive part of the research process. Its role was limited to supporting the manuscript preparation and editorial process.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Disclaimer There was no confilct of interest

Competing interests none

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Yau-Ren Chang http://orcid.org/0000-0003-4968-2746
Yu-Tung Wu http://orcid.org/0000-0002-2145-8710
Szu An Chen http://orcid.org/0000-0003-1270-4788
Chih-Yuan Fu http://orcid.org/0000-0003-1536-1549
Chi-Tung Cheng http://orcid.org/0000-0002-2697-4642
Ling-Wei Kuo http://orcid.org/0000-0001-6489-3723
Jen Fu Huang http://orcid.org/0000-0001-8185-8372
Chien-Hung Liao http://orcid.org/0000-0003-2812-9773
Chi-Hsun Hsieh http://orcid.org/0000-0003-2021-9555

REFERENCES

- 1 Arvieux C, Thony F, Broux C, Ageron F-X, Rancurel E, Abba J, Faucheron J-L, Rambeaud J-J, Tonetti J. Current management of severe pelvic and perineal trauma. *J Visc Surg* 2012;149:e227–38.
- 2 Cullinane DC, Schiller HJ, Zielinski MD, Bilaniuk JW, Collier BR, Como J, Holevar M, Sabater EA, Sems SA, Vassy WM, et al. Eastern Association for the Surgery of Trauma practice management guidelines for hemorrhage in pelvic fracture--update and systematic review. J Trauma 2011;71:1850–68.
- 3 Magnone S, Coccolini F, Manfredi R, Piazzalunga D, Agazzi R, Arici C, Barozzi M, Bellanova G, Belluati A, Berlot G, et al. Management of hemodynamically unstable pelvic trauma: results of the first Italian consensus conference (cooperative guidelines of the Italian Society of Surgery, the Italian Association of Hospital Surgeons, the Multi-specialist Italian Society of Young Surgeons, the Italian Society of Emergency Surgery and Trauma, the Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care, the Italian Society of Orthopaedics and Traumatology, the Italian Society of Emergency Medicine, the Italian Society of Medical Radiology -Section of Vascular and Interventional Radiology- and the World Society of Emergency Surgery). World J Emerg Surg 2014;9:18.
- 4 Grotz MRW, Allami MK, Harwood P, Pape HC, Krettek C, Giannoudis PV. Open pelvic fractures: epidemiology, current concepts of management and outcome. *Injury* 2005;36:1–13.
- 5 Perkins ZB, Maytham GD, Koers L, Bates P, Brohi K, Tai NRM. Impact on outcome of a targeted performance improvement programme in haemodynamically unstable patients with a pelvic fracture. *Bone Joint J* 2014;96-B:1090–7.
- 6 Coccolini F, Stahel PF, Montori G, Biffl W, Horer TM, Catena F, Kluger Y, Moore EE, Peitzman AB, Ivatury R, et al. Pelvic trauma: WSES classification and guidelines. World J Emerg Surg 2017;12:5.
- 7 Brown JV, Yuan S. Traumatic Injuries of the Pelvis. Emerg Med Clin North Am 2020;38:125–42.
- 8 Jarvis S, Kelly M, Mains C, Corrigan C, Patel N, Carrick M, Lieser M, Banton K, Bar-Or D. A descriptive survey on the use of resuscitative endovascular balloon occlusion of the aorta (REBOA) for pelvic fractures at US level I trauma centers. Pat Saf Surg 2019;13:43.
- 9 Metsemakers W-J, Vanderschot P, Jennes E, Nijs S, Heye S, Maleux G. Transcatheter embolotherapy after external surgical stabilization is a valuable treatment algorithm for patients with persistent haemorrhage from unstable pelvic fractures: outcomes of a single centre experience. *Injury* 2013;44:964–8.
- 10 Broadwell SR, Ray CE. Transcatheter Embolization in Pelvic Trauma. Semin intervent Radiol 2004;21:23–35.
- 11 Özkurtul O, Staab H, Osterhoff G, Ondruschka B, Höch A, Josten C, Fakler JKM. Technical limitations of REBOA in a patient with exsanguinating pelvic crush trauma: a case report. *Pat Saf Surg* 2019;13:25.
- Manzano-Nunez R, Orlas CP, Herrera-Escobar JP, Galvagno S, DuBose J, Melendez JJ, Serna JJ, Salcedo A, Peña CA, Angamarca E, et al. A meta-analysis of the incidence of complications associated with groin access after the use of resuscitative endovascular



- balloon occlusion of the aorta in trauma patients. *J Trauma Acute Care Surg* 2018;85:626–34.
- 13 Hurley S, Erdogan M, Kureshi N, Casey P, Smith M, Green RS. Comparison of clinical and anatomical criteria for resuscitative endovascular balloon occlusion of the aorta (REBOA) among major trauma patients in Nova Scotia. CJEM 2021;23:528–36.
- 14 Harfouche M, Inaba K, Cannon J, Seamon M, Moore E, Scalea T, DuBose J. Patterns and outcomes of zone 3 REBOA use in the management of severe pelvic fractures: Results from the AAST Aortic Occlusion for Resuscitation in Trauma and Acute Care Surgery database. J Trauma Acute Care Surg 2021;90:659–65.
- 15 Russo RM, Williams TK, Grayson JK, Lamb CM, Cannon JW, Clement NF, Galante JM, Neff LP. Extending the golden hour: Partial resuscitative endovascular balloon occlusion of the aorta in a highly lethal swine liver injury model. J Trauma Acute Care Surg 2016;80:372–8;
- 16 Kuckelman J, Derickson M, Barron M, Phillips CJ, Moe D, Levine T, Kononchik JP, Marko ST, Eckert M, Martin MJ. Efficacy of intermittent versus standard resuscitative endovascular balloon occlusion of the aorta in a lethal solid organ injury model. J Trauma Acute Care Surg 2019;87:9–17.
- 17 Nguyen P, Makris A, Hennessy A, Jayanti S, Wang A, Park K, Chen V, Nguyen T, Lo S, Xuan W, et al. Standard versus ultrasound-guided radial and femoral access in coronary angiography and intervention (SURF): a randomised controlled trial. EuroIntervention 2019;15:e522–30.
- 18 Awwad A, Dhillon PS, Ramjas G, Habib SB, Al-Obaydi W. Trans-arterial embolisation (TAE) in haemorrhagic pelvic injury: review of management and mid-term outcome of a major trauma centre. CVIR Endovasc 2018;1:32.

- 19 Borger van der Burg BLS, van Dongen TTCF, Morrison JJ, Hedeman Joosten PPA, DuBose JJ, Hörer TM, Hoencamp R. A systematic review and meta-analysis of the use of resuscitative endovascular balloon occlusion of the aorta in the management of major exsanguination. Eur J Trauma Emerg Surg 2018;44:535–50.
- 20 Matsumura Y, Matsumoto J, Kondo H, Idoguchi K, Ishida T, Kon Y, Tomita K, Ishida K, Hirose T, Umakoshi K, et al. Fewer REBOA complications with smaller devices and partial occlusion: evidence from a multicentre registry in Japan. Emerg Med J 2017;34:793–9.
- 21 Ribeiro Junior MAF, Feng CYD, Nguyen ATM, Rodrigues VC, Bechara GEK, de-Moura RR, Brenner M. The complications associated with Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA). World J Emerg Surg 2018:13:20.
- 22 Norii T, Crandall C, Terasaka Y. Survival of severe blunt trauma patients treated with resuscitative endovascular balloon occlusion of the aorta compared with propensity score-adjusted untreated patients. J Trauma Acute Care Surg 2015;78:721–8.
- 23 Matsumura Y, Matsumoto J, Kondo H, Idoguchi K, Ishida T, Okada Y, Kon Y, Oka K, Ishida K, Toyoda Y, et al. Early arterial access for resuscitative endovascular balloon occlusion of the aorta is related to survival outcome in trauma. J Trauma Acute Care Surg 2018;85:507–11.
- 24 Sadeghi M, Dogan EM, Karlsson C, Jansson K, Seilitz J, Skoog P, Hörer TM, Nilsson KF. Total resuscitative endovascular balloon occlusion of the aorta causes inflammatory activation and organ damage within 30 minutes of occlusion in normovolemic pigs. BMC Surg 2020;20:43.